Author

Madhavi Yadavalli

Institution: AstraZeneca (United States)

Observed institution: AstraZeneca (United States)

OpenAlex ID: A5011651995

Very rare thrombosis with thrombocytopenia after second AZD1222 dose: a global safety database analysis

2021 · Prakash Bhuyan, Jennie Medin, et al. · The Lancet · 68

Geographical distribution of TTS cases following AZD1222 (ChAdOx1 nCoV-19) vaccination

2021 · Karina Soboleva, Nirmal Kumar Shankar, et al. · The Lancet Global Health · 26

Thrombosis with thrombocytopenia after AZD1222 (ChAdOx1 nCov-19) vaccination: Case characteristics and associations

2022 · Michael A Laffan, Sue Rees, et al. · Vaccine · 11

Tozorakimab to Prevent COPD Exacerbations

2026 · Frank C. Sciurba, Henrik Watz, et al. · New England Journal of Medicine · 10

Late Breaking Abstract - Tozorakimab to prevent COPD exacerbations: results from the replicate OBERON and TITANIA phase 3 studies

2026 · Frank Sciurba, Henrik Watz, et al. · European Respiratory Journal

Just how common is TTS after a second dose of the ChAdOx1 nCov-19 vaccine? – Authors’ reply

2021 · Prakash Bhuyan, Jennie Medin, et al. · The Lancet

Works count: 6

Citation count: 115

H-index: 4

I10-index: 4